| Title |
|
Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. |
|
|
| Publication Date |
|
| Author(s) |
|
Rainey-Smith, Stephanie R |
|
|
| Subject |
|
blood diagnostic for Alzheimer's disease |
|
|
positron emission tomography |
|
|
| Type of document |
|
| OrcId |
|
https://orcid.org/0000-0002-8051-0558 |
|
|
https://orcid.org/0000-0002-5374-2839 |
|
|
https://orcid.org/0000-0003-1397-0359 |
|
|
https://orcid.org/0000-0001-8259-9069 |
|
|
https://orcid.org/0000-0003-3072-7940 |
|
|
https://orcid.org/0000-0002-5832-9875 |
|
|
https://orcid.org/0000-0003-3910-2453 |
|
|
| DOI |
|
| Abstract |
|
We evaluated a new Simoa plasma assay for phosphorylated tau (P-tau) at aa217 enhanced by additional p-tau sites (p217+tau). Plasma p217+tau levels were compared to 18F-NAV4694 amyloid beta (Aβ) positron emission tomography (PET) and 18F-MK6240 tau PET in 174 cognitively impaired (CI) and 223 cognitively unimpaired (CU) participants. Compared to Aβ- CU, the plasma levels of p217+tau increased 2-fold in Aβ+ CU and 3.5-fold in Aβ+ CI. In Aβ- the p217+tau levels did not differ significantly between CU and CI. P217+tau correlated with Aβ centiloids P = .67 (CI, P = .64; CU, P = .45) and tau SUVRMT P = .63 (CI, P = .69; CU, P = .34). Area under curve (AUC) for Alzheimer's disease (AD) dementia versus Aβ- CU was 0.94, for AD dementia versus other dementia was 0.93, for Aβ+ versus Aβ- PET was 0.89, and for tau+ versus tau- PET was 0.89. Plasma p217+tau levels elevate early in the AD continuum and correlate well with Aβ and tau PET. |
|
|
| Link |
|
| Citation |
|
Alzheimer's & Dementia (Amsterdam, Netherlands) 2022; 14(1): e12307 |
|
|
| Jornal Title |
|
Alzheimer's & Dementia (Amsterdam, Netherlands) |
|
|
| ISSN |
|